TIMI 12

OBJECTIVE: To evaluate the safety and efficacy of the oral GP IIb/IIa inhibitor sibrafiban for the treatment of patients with a recent acute coronary syndrome.

View/Download
_______________________________________________________________________________

1. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Cannon CP, McCabe CH, Borzak S, et al. Circulation 1998;97:340-9.
   | Abstract | Request Reprints |
   
   

2. PlA2 polymorphism of the platelet IIb/IIIa receptor: increased risk of early recurrent ischemic events in acute coronary syndromes, increased platelet aggregability, and effective platelet inhibition by an oral IIb/IIIa inhibitor: results from TIMI 12. Cannon CP, Bray PF, Ault KA, Rizzo MJ, Braunwald E. Circulation 1998;98(Suppl. I):I-171.
   | Request Reprints |
   
   
3. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. Ault KA, Cannon CP, Mitchell J, et al. J Am Coll Cardiol 1999;33:634-9.
   | Abstract | Request Reprints |